Baxter Announces Biologics Capacity Expansion
News Apr 20, 2012
Baxter International Inc. announced it will build a new state-of-the-art manufacturing facility in Georgia to support growth of its plasma-based treatments. These therapies include treatments for immune disorders, trauma and other critical conditions.
Baxter expects capital investments at the Covington, Ga., site to exceed $1 billion over the next five years and to result in the creation of more than 1,500 full-time positions in Georgia and more than 2,000 jobs in total across multiple U.S. locations.
''This investment demonstrates our long-term commitment to patients around the world who rely on our plasma-based therapies,'' said Robert L. Parkinson, Jr., Baxter's chairman and chief executive officer.
Construction will begin this year at the new Covington site, which will include operations supporting plasma fractionation, purification, fill-finish and a testing lab. Commercial production is scheduled to begin in 2018, with the new plasma fractionation facility adding up to three million liters of new capacity annually when fully operational.
The Covington site will have the flexibility and necessary infrastructure to expand further to support additional global market needs.
''We would like to thank Governor Nathan Deal and the many other officials involved in the site selection process, and we look forward to becoming part of the Georgia community,'' said Ludwig Hantson, Ph.D., president of Baxter's BioScience business.
In connection with this investment, the company also expects to create more than two hundred new positions in Illinois, including jobs associated with expanded filling and finishing capacity at its existing manufacturing facility in Round Lake, Ill. The new jobs at the Round Lake facility will support production of FLEXBUMIN, a preparation of plasma-based albumin treatment in a flexible container.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE